Available option
5mg
Lyophilised powder
- Strength
- 5mg
- Format
- Lyophilised powder
Bear Biotech catalogue
LL-37
Human cathelicidin-derived host-defence peptide research material
- Host-defence peptide biology
- Membrane interactions
- Innate immune signalling
Available presentations
Choose a strength and format
Each available presentation is listed separately. Current prices are confirmed from the Bear Biotech catalogue.
Research overview
What is LL-37?
LL-37 is the 37-residue antimicrobial peptide generated from the human cathelicidin precursor hCAP18. It is widely studied in membrane biology, antimicrobial assays, chemotaxis, epithelial signalling and innate immune responses. Its activity is strongly context- and concentration-dependent, making careful experimental design essential.
Extensive in-vitro and preclinical host-defence biology; not an established generic therapeutic product.
Research focus
Key research areas
LL-37 research: human cathelicidin and host-defence biology
LL-37 is the 37-residue C-terminal peptide generated from human cathelicidin hCAP18. Laboratory studies measure membrane, chemotaxis and innate-signalling activity. Published findings concern defined experimental materials and do not establish the identity, quality, safety, efficacy or equivalence of Bear Biotech catalogue material.
- Host-defence peptide biology
- Membrane interactions
- Innate immune signalling
Representative primary research
Representative research
Research includes direct antimicrobial assays, membrane structure/activity, FPRL1-linked chemotaxis, epithelial signalling and innate/adaptive immune-cell recruitment.
- Activities of LL-37 ↗ Primary antimicrobial assay study; activity depends on the experimental system and does not establish a treatment claim.
- hCAP18 processed to LL-37 by proteinase 3 ↗ Primary mechanistic study of endogenous processing; it does not establish catalogue material equivalence.
- LL-37 uses FPRL1 to chemoattract immune cells ↗ Primary mechanistic study; it does not establish a treatment outcome or catalogue material equivalence.
These sources provide research context only. They do not verify the identity, quality or equivalence of a Bear Biotech catalogue batch; the matched lot-specific batch record remains controlling.
Specifications
Product information
- Material identity
- LL-37
- Research category
- Human cathelicidin-derived host-defence peptide research material
- Evidence position
- Extensive in-vitro and preclinical host-defence biology; not an established generic therapeutic product.
- Recorded formats
- Lyophilised powder
- Batch-record basis
- The matched lot-specific record controls identity and analytical claims.
- Intended use
- Controlled laboratory research only.
Research questions
Evidence and identity questions
Why is LL-37 classified as a human host-defence peptide?
LL-37 is studied as a human host-defence peptide with membrane-interaction and innate-immune signalling functions. Research spans microbial and immune models.
How do concentration and model choice affect LL-37 membrane studies?
Membrane and immune experiments use different concentrations, systems and endpoints. Results can vary substantially with model and material handling.
Why does extensive preclinical biology not establish LL-37 as a generic therapy?
LL-37 has extensive in-vitro and preclinical host-defence research. It is not an established generic therapeutic product.
Batch documentation
Lot-specific records stay connected to the order
Eligible lot-specific documentation may be viewed or requested from the registered Bear Biotech account when available for the applicable order.
Open Bear Biotech accountResearch use only
Controlled laboratory research material
Not for human or veterinary consumption. Administration, dosing and therapeutic guidance are not provided.